Lunai Bioworks signs agreement with BrainStorm Therapeutics to unlock new avenues in drug discovery for Parkinson's disease
04 August 2026
Sacramento-based Lunai Bioworks, Inc., an AI-driven platform for precision medicine, announced the execution of a Master Collaboration Agreement with BrainStorm Therapeutics Inc., an AI-powered precision neuroscience company developing disease-modifying therapies using patient-derived human brain organoids.
In parallel, Lunai's subsidiary BioSymetrics Inc. published a new technical white paper, "Phenoclustering Parkinson's Disease to Uncover New Targets and Biomarkers". The agreement and white paper establish an integrated workflow that combines BioSymetrics' patented Contingent AI™ patient-stratification platform with BrainStorm's NVIDIA- and California Life Sciences-award-winning AI-powered human brain organoid platform.
Parkinson's disease is a progressive, multifactorial, and heterogeneous disorder with a poorly understood etiology and limited treatment options. With the rapid rise of Parkinson's disease incidence and the growing public health burden, finding disease-modifying treatments to slow, halt and reverse its progression is a huge unmet need.
The BioSymetrics white paper describes how the company's Contingent AI™ platform analyzed the Parkinson's Progression Markers Initiative dataset to identify clinically distinct Parkinson's disease subtypes. By linking baseline patient characteristics with longitudinal clinical outcomes and proteomic signatures, the analysis provides a foundation for precision patient stratification, biomarker discovery, and therapeutic target identification.
BrainStorm combines modeling of human neurodevelopmental and neurodegenerative diseases with advanced machine learning to generate more predictive insights into disease biology and drug efficacy. By integrating human genetics, single-cell transcriptomics, functional phenotyping, and AI, BrainStorm's platform allows to identify patient subtype-specific disease mechanisms as well as convergent disease mechanisms shared across familial and sporadic forms of Parkinson's disease, as well as to prioritize disease-modifying therapeutic targets across these patient groups.
The main goal of this collaboration is to translate computationally identified patient subtypes into experimentally validated disease mechanisms, biomarkers, therapeutic targets, and partner-ready drug-development opportunities.
"Parkinson's disease is not one biological entity and treating it as a single disease has contributed to repeated clinical-development challenges," said David Weinstein, Chief Executive Officer of Lunai Bioworks. "Our strategy is to turn that heterogeneity into a development advantage. Near term, our platform can help partners design sharper clinical trials by identifying which patients to include, which patients may dilute a treatment signal, and which endpoints are most appropriate. Medium term, we are advancing biomarker panels that could support precision patient selection. Longer term, our collaboration with BrainStorm adds the human translational validation required to build partner-ready therapeutic programs."
"BioSymetrics and BrainStorm bring complementary AI and translational capabilities to precision neuroscience," said Robert T. Fremeau, Jr., Ph.D., Founder and Chief Executive Officer of BrainStorm Therapeutics. "BioSymetrics identifies clinically meaningful Parkinson's disease subtypes, biomarkers, and therapeutic hypotheses from complex patient datasets. BrainStorm then applies a lab-in-the-loop approach, using patient-derived human midbrain organoids to test these hypotheses, generate new biological data, refine our AI models, identify convergent disease mechanisms, and prioritize and experimentally validate therapeutic targets in a human genetic context. Together, we are creating an iterative path from patient stratification to human biological validation and, ultimately, to the development of disease-modifying therapies for defined groups of Parkinson's disease patients."
"This represents the execution of our broader Parkinson's strategy," added Weinstein. "The white paper establishes the computational foundation. Our agreement with BrainStorm provides the translational validation engine. Together, they create an integrated pathway from patient stratification through biomarker development and human biological validation to commercial pharmaceutical partnerships."
For weekly news, trends and insights on human‑based in vitro approaches, explore your access options.
